AUTHORS
Efstathios Kastritis, MD, Anita D'Souza Jr, MD2, Rajshekhar Chakraborty, MD3, Angela Dispenzieri, MD4, Antoine Huart5, Shinsuke Iida, PhD6, Tadao Ishida, MD, PhD7, Shaji Kumar, MD8, Heather J. Landau, MD9, Jin Lu10, Peter Mollee, MBBS, MSc, FRACP, FRCPA11, Stefan Schönland, MD, PhD12, Ashutosh D. Wechalekar, MD13, Emma L. Arriola, PhD14, Faisal Rahman15, Mark Rocco, PhD16, Cara Rosenbaum17, Jovian Yu, MD, MS, MBA18, Giovanni Palladini, MD,PhD19, Vaishali Sanchorawala, MD20
AFFILIATIONS
1 National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
2 Froedtert & Medical College of Wisconsin Cancer Center, Milwaukee, Wisconsin, United States
3 Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, New York, United States
4 Mayo Clinic, Rochester, Minnesota, United States
5 University Hospital Toulouse, Toulouse, France
6 Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
7 Japanese Red Cross Medical Center, Tokyo, Japan
8 Mayo Clinic, Rochester, Minnesota, United States
9 Memorial Sloan Kettering Cancer Center, New York, New York, United States
10 Peking University People's Hospital, Beijing, China
11 Princess Alexandra Hospital, Brisbane, Australia, University of Queensland, Brisbane, Australia
12 University Hospital Heidelberg, Heidelberg, Germany
13 University College London Hospital and National Amyloidosis Center (UCL Royal Free Campus), London, United Kingdom
14 AbbVie Inc., North Chicago, Illinois, United States
15 AbbVie, North Chicago, Illinois, United States
16 AbbVie Inc., North Chicago, Illinois, United States
17 AbbVie Inc., North Chicago, Illinois, United States
18 AbbVie Inc., North Chicago, Illinois, United States
19 Foundation 'Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo', Pavia, Italy, University of Pavia, Pavia, Italy
20 Boston University Chobanian & Avedisian School of Medicine Medical Center, Boston, United States
ABSTRACT
Background: AL amyloidosis prognosis is determined by extent of organ involvement alongside time to hematologic complete response (hemeCR). While Dara-CyBorD improves outcomes, ~40% of patients fail to achieve hemeCR, leaving them at risk of organ progression and death.
Etentamig is being developed as a next-generation differentiated BCMAxCD3 bispecific T-cell engager, optimized for convenient monthly (Q4W) dosing from the start, and composed of a bivalent BCMA-binding domain with high avidity, and a low-affinity CD3-binding domain potentially reducing CRS and infection rates. BCMA is highly expressed on amyloidogenic light chain-producing plasma cells and is a promising therapeutic target. Phase 1b dose escalation (N=34) of Study M24-209 (NCT06158854) evaluating etentamig in patients with relapsed/refractory AL amyloidosis demonstrated strong efficacy (100% hemeCR) and compelling safety (9% CRS, G1 only; no ICANS; 6% G3 infections, no G4), supporting investigation of etentamig in ND AL amyloidosis.
Methods: ENTRUST-AL is a phase 3, multicenter, randomized, active-controlled, open-label, registrational study evaluating etentamig monotherapy compared with Dara-CyBorD in adults with ND AL amyloidosis. After a safety run-in (N=20), ~350 additional patients will be randomized 1:1 to receive etentamig monotherapy or Dara-CyBorD for 24 cycles. Key eligibility criteria include: histopathological diagnosis of amyloidosis, evidence of monoclonal plasma cell disorder, dFLC ≥50 mg/L, ≥1 systemic organ impacted by AL amyloidosis, cardiac risk stage 1–3a (or 3b [randomized portion only]), adequate liver and bone marrow function, eGFR ≥20 mL/min/1.73m2 (by CKD-EPI), ECOG PS≤2, and no prior anti-amyloidosis therapy. Dual primary endpoints are hemeCR rate and MOD-PFS (includes high-risk dFLC progression criteria). Secondary endpoints include organ response rates, overall survival, and patient-reported outcomes.
DISCLOSURES
Efstathios Kastritis, MD: Genesis Pharma - Honoraria; GSK - Honoraria; Pfizer - Honoraria; Johnson and Johnson - Honoraria; Abbvie - Honoraria; Pfizer - Research Funding; Johnson and Johnson - Research Funding; GSK - Research Funding; Abbvie - Consultancy (Includes expert testimony); Johnson and Johnson - Consultancy (Includes expert testimony); GSK - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony)